Metabolic substrate

Primarily metabolized via UGT1A1 with some contribution from CYP3A. Renal elimination of unchanged drug was low (< 1% of the dose). UGT1A9 and 1A3, P-gp and BCRP (in vitro)

Metabolic inducer

–

Metabolic inhibitor

OCT2 and MATE 1

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–

Metabolic substrate

Mainly eliminated renally (60-70%) and also partly hydroxylated via multiple CYPs.

Metabolic inducer

–

Metabolic inhibitor

–

Pharmacodynamic effects

–

Recommendations

–

Alternative solution(s)

–